Catalent, novo nordisk
Catalent gains on report it's likely to be granted EU approval for Novo Holdings deal
Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings, the parent of Ozempic maker Novo Nordisk (NVO). The European Commission is expected to give ...
Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock from a Hold ...
GlobalData on MSN3d
Melt reports topline outcomes from trial of MELT-300 for cataract surgeryMelt Pharmaceuticals has reported encouraging topline results from its Phase III trial of MELT-300, a non-intravenous, ...
Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for ...
On Friday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.41 which represents a decrease of $-0.51 or -0.85% from the prior close of $59.92. The stock opened at $59.81 and touched a ...
With a market cap of $10.7 billion, Catalent, Inc. (CTLT) is a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...
CIBC Asset Management Inc grew its holdings in shares of Catalent, Inc. (NYSE:CTLT – Free Report) by 7.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback